{"id":53879,"date":"2023-02-13T23:06:37","date_gmt":"2023-02-13T22:06:37","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/seagen-to-highlight-research-in-urothelial-cancer-at-the-2023-american-society-of-clinical-oncology-genitourinary-cancers-symposium\/"},"modified":"2023-02-13T23:06:37","modified_gmt":"2023-02-13T22:06:37","slug":"seagen-to-highlight-research-in-urothelial-cancer-at-the-2023-american-society-of-clinical-oncology-genitourinary-cancers-symposium","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/seagen-to-highlight-research-in-urothelial-cancer-at-the-2023-american-society-of-clinical-oncology-genitourinary-cancers-symposium\/","title":{"rendered":"Seagen to Highlight Research in Urothelial Cancer at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium"},"content":{"rendered":"
\n

\n– Data presentations demonstrate continued potential of <\/i>PADCEV\u00ae<\/sup> (enfortumab vedotin-ejfv) in multiple types of urothelial cancer –<\/i>\n<\/p>\n

\n– Patient-reported outcomes underscore Seagen\u2019s commitment to addressing patients\u2019 needs and quality of life –<\/i>\n<\/p>\n

BOTHELL, Wash.–(BUSINESS WIRE)–Seagen Inc.<\/a> (Nasdaq: SGEN) today announced the presentation of new data featuring PADCEV\u00ae<\/sup> (enfortumab vedotin-ejfv) at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) taking place from February 16-18, 2023. A podium presentation will feature noteworthy patient-reported outcomes from the registrational Phase 1b\/2 EV\u2010103 Cohort K study.\n<\/p>\n

<\/a><\/p>\n

\nCohort K is evaluating enfortumab vedotin developed in partnership with Astellas, as monotherapy and in combination with Merck\u2019s anti-PD-1 therapy KEYTRUDA\u00ae<\/sup> (pembrolizumab) as first-line treatment in patients with unresectable locally advanced or metastatic urothelial cancer (la\/mUC) who are ineligible to receive cisplatin-based chemotherapy. Merck is known as MSD outside the United States and Canada.\n<\/p>\n

\n\u201cPatients are at the heart of the work we do, and we are committed to developing innovative solutions for people with urothelial cancer and challenging clinical needs,\u201d said Marjorie Green, M.D., Senior Vice President and Head of Late-Stage Development, Seagen. \u201cWe look forward to presenting patient-reported outcomes for PADCEV at ASCO GU, and further addressing unmet needs that people with cancer experience in order to better support this community and increase their quality of life.\u201d\n<\/p>\n

\nOther notable data that will be presented from Seagen\u2019s sponsored research include subgroup analyses of the confirmed objective response rate by investigator assessment from the EV\u2010103 Cohort K study, along with qualitative insights from patients, caregivers and physicians and data from real-world studies. Trials in progress for enfortumab vedotin in non-muscle invasive and muscle-invasive bladder cancer will also be featured in poster presentations at the meeting, showcasing Seagen\u2019s engagement across a broad spectrum of urothelial cancers.\n<\/p>\n

\nKey data presentations for Seagen include:\n<\/p>\n

\nPresentations of Company-Sponsored Trials<\/b>\n<\/p>\n\n\n\n\n\n\n\n\n\n\n
\n

\nAbstract Title<\/b>\n<\/p>\n<\/td>\n

\n

\nAbstract #<\/b>\n<\/p>\n<\/td>\n

\n

\nPresentation Time<\/b>\n<\/p>\n<\/td>\n

\n

\nLead Author<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nEnfortumab Vedotin\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nPatient\u2010reported outcomes (PROs) in cisplatin\u2010ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la\/mUC) treated with enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in the Phase 1b\/2 EV\u2010103 Cohort K study\n<\/p>\n<\/td>\n

\n

\n439\n<\/p>\n<\/td>\n

\n

\nPodium Presentation
\n
Friday, Feb. 17\n<\/p>\n

\n3:45-3:55 p.m. PT\n<\/p>\n

\n\u00a0\n<\/p>\n

\nPanel Discussion\n<\/p>\n

\n3:55 p.m. PT\n<\/p>\n<\/td>\n

\n

\nM. Milowsky\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nEnfortumab vedotin (EV) alone or in combination w\/ pembrolizumab (P) in previously untreated cisplatin\u2010ineligible patients w\/ locally advanced or metastatic urothelial cancer (la\/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV\u2010103 Cohort K\n<\/p>\n<\/td>\n

\n

\n499\n<\/p>\n<\/td>\n

\n

\nPoster Session\n<\/p>\n

\nFriday, Feb. 17\n<\/p>\n

\n12:30-2 p.m. PT\n<\/p>\n

\n5:15-6:15 p.m. PT\n<\/p>\n<\/td>\n

\n

\nP. O\u2019Donnell\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nUnderstanding drivers of treatment preferences in locally advanced or metastatic urothelial carcinoma: A qualitative interview study with patients, caregivers, and physicians\n<\/p>\n<\/td>\n

\n

\n492\n<\/p>\n<\/td>\n

\n

\nPoster Session
\n
Friday, Feb. 17\n<\/p>\n

\n12:30-2 p.m. PT\n<\/p>\n

\n5:15-6:15 p.m. PT\n<\/p>\n<\/td>\n

\n

\nA. Apolo\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nReal\u2010World treatment and quality of life (QOL) in locally advanced or metastatic urothelial carcinoma (la\/mUC) in Saudi Arabia, Singapore, South Korea, Taiwan, and Turkey\n<\/p>\n<\/td>\n

\n

\n462\n<\/p>\n<\/td>\n

\n

\nPoster Session
\n
Friday, Feb. 17\n<\/p>\n

\n12:30-2 p.m. PT\n<\/p>\n

\n5:15-6:15 p.m. PT\n<\/p>\n<\/td>\n

\n

\nL. Cheng\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nReal\u2010World treatment patterns, survival outcomes, and health care resource utilization (HCRU) for Locally Advanced or Metastatic Urothelial Carcinoma (la\/mUC) in Spain\n<\/p>\n<\/td>\n

\n

\n463\n<\/p>\n<\/td>\n

\n

\nPoster Session
\n
Friday, Feb. 17\n<\/p>\n

\n12:30-2 p.m. PT\n<\/p>\n

\n5:15-6:15 p.m. PT\n<\/p>\n<\/td>\n

\n

\nJ. Puente\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nDisitamab Vedotin\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nSystematic literature review and testing of HER2 status in urothelial carcinoma (UC)\n<\/p>\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n556\n<\/p>\n<\/td>\n

\n

\nPoster Session
\n
Friday, Feb. 17\n<\/p>\n

\n12:30-2 p.m. PT\n<\/p>\n

\n5:15-6:15 p.m. PT\n<\/p>\n<\/td>\n

\n

\nV. Koshkin\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nPresentations of Company-Sponsored Trials in Progress<\/b>\n<\/p>\n\n\n\n\n\n\n\n\n\n\n
\n

\nAbstract Title<\/b>\n<\/p>\n<\/td>\n

\n

\nAbstract #<\/b>\n<\/p>\n<\/td>\n

\n

\nPresentation Type<\/b>\n<\/p>\n<\/td>\n

\n

\nLead Author<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nEnfortumab Vedotin\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nStudy EV\u2010104: Phase 1 study of intravesical enfortumab vedotin for treatment of patients with non\u2010muscle invasive bladder cancer (NMIBC) (Encore)\n<\/p>\n

\n(TIP)\n<\/p>\n<\/td>\n

\n

\nTPS582\n<\/p>\n<\/td>\n

\n

\nPoster Session
\n
Friday, Feb. 17\n<\/p>\n

\n12:30 p.m. PT\n<\/p>\n<\/td>\n

\n

\nA. Kamat\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nPhase 3 KEYNOTE\u2010905\/EV\u2010303: Perioperative pembrolizumab (pembro) or pembro + enfortumab vedotin (EV) for muscle\u2010invasive bladder cancer (MIBC) (Encore) (TIP)\n<\/p>\n<\/td>\n

\n

\nTPS585\n<\/p>\n<\/td>\n

\n

\nPoster Session
\n
Friday, Feb. 17\n<\/p>\n

\n12:30 p.m. PT\n<\/p>\n<\/td>\n

\n

\nA. Necchi\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nPerioperative enfortumab vedotin (EV) plus pembrolizumab (pembro) versus chemotherapy in cisplatin\u2010eligible patients (pts) with muscle\u2010invasive bladder cancer (MIBC): Phase 3 KEYNOTE\u2010B15\/EV\u2010304 (Encore) (TIP)\n<\/p>\n<\/td>\n

\n

\nTPS588\n<\/p>\n<\/td>\n

\n

\nPoster Session
\n
Friday, Feb. 17\n<\/p>\n

\n12:30 p.m. PT\n<\/p>\n<\/td>\n

\n

\nC. Hoimes\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTucatinib\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nA Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations: urothelial cancer cohort (TIP)\n<\/p>\n<\/td>\n

\n

\nTPS587\n<\/p>\n<\/td>\n

\n

\nPoster Session
\n
Friday, Feb. 17\n<\/p>\n

\n12:30 p.m. PT\n<\/p>\n<\/td>\n

\n

\nE. Yu\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nDisitamab Vedotin\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nA Phase 2 clinical study evaluating the efficacy and safety of disitamab vedotin with or without pembrolizumab in patients with HER2-expressing urothelial carcinoma (TIP)\n<\/p>\n<\/td>\n

\n

\nTPS594\n<\/p>\n<\/td>\n

\n

\nPoster Session
\n
Friday, Feb. 17\n<\/p>\n

\n12:30 p.m. PT\n<\/p>\n<\/td>\n

\n

\nT. Powles\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nAbout Enfortumab Vedotin<\/b>\n<\/p>\n

\nEnfortumab vedotin is an antibody-drug conjugate (ADC) that is directed against Nectin-4, a protein located on the surface of cells and highly expressed in bladder cancer.i,ii<\/sup> Nonclinical data suggest the anticancer activity of enfortumab vedotin is due to its binding to Nectin-4 expressing cells followed by the internalization and release of the anti-tumor agent monomethyl auristatin E (MMAE) into the cell, which result in the cell not reproducing (cell cycle arrest) and in programmed cell death (apoptosis).i\n<\/p>\n

\nPADCEV (enfortumab vedotin-ejfv) U.S. Indication & Important Safety Information
\n
<\/b>BOXED WARNING: SERIOUS SKIN REACTIONS<\/b>\n<\/p>\n